MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer

Annals of Oncology

Volumn 20, Issue 10, 2009, Pages 1660-1666

  Afzal, Shoiab ^a   Jensen, S A ^a   Vainer, B ^a   Vogel, U ^b,c   Matsen, J P ^a   Sorensen J B ^a   Andersen, P K ^d   Poulsen, H E ^a  

^a Rigshospitalet   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c ROSKILDE UNIVERSITY   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

5 fluorouracil; Colorectal cancer; Methylenetetrahydrofolate reductase; Pharmacogenetics; Single nucleotide polymorphisms

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADENOSINE; CYTIDINE; DNA; FLUOROURACIL; FOLINATE CALCIUM; THYMIDINE;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DNA EXTRACTION; DRUG EFFICACY; FEMALE; HAPLOTYPE; HUMAN; HUMAN TISSUE; INFECTION; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DENMARK; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FLUOROURACIL; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NEOPLASM STAGING; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 70349646312     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp046     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2): 74-108.
2. Cheradame S, Etienne MC, Chazal M et al. Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal 5-fluorouracil efficacy: Experimental data. Eur J Cancer 1997; 33(6): 950-959.
3. Danenberg PV, Danenberg KD. Effect of 5, 10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthetase: Evidence for an ordered mechanism. Biochemistry 1978; 17(19): 4018-4024.
4. Houghton JA, Maroda SJ Jr, Phillips JO, Houghton PJ. Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res 1981; 41(1): 144-149.
5. Keyomarsi K, Moran RG. Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells. J Biol Chem 1988; 263(28): 14402-14409.
6. Canman CE, Tang HY, Normolle DP et al. Variations in patterns of DNA damage induced in human colorectal tumor cells by 5-fluorodeoxyuridine: implications for mechanisms of resistance and cytotoxicity. Proc Natl Acad Sci U S A 1992; 89(21): 10474-10478.
7. Yoshioka A, Tanaka S, Hiraoka O et al. Deoxyribonucleoside triphosphate imbalance. 5-Fluorodeoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. J Biol Chem 1987; 262(17): 8235-8241.
8. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA 1988; 259(24): 3571-3578.
9. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992; 10(6): 896-903.
10. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345(8955): 939-944.
11. Thirion P, Michiels S, Pignon JP et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: An updated meta-analysis. J Clin Oncol 2004; 22(18): 3766-3775.
12. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10(1): 111-113.
13. van der Put NM, Gabreels F, Stevens EM et al. A second common mutation in the methylenetetrahydrofolate reductase gene: An additional risk factor for neural-tube defects? Am J Hum Genet 1998; 62(5): 1044-1051.
14. Weisberg I, Tran P, Christensen B et al. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64(3): 169-172.
15. Etienne MC, Ilc K, Formento JL et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: Relationships with 5-fluorouracil sensitivity. Br J Cancer 2004; 90(2): 526-534.
16. Sohn KJ, Croxford R, Yates Z et al. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 2004; 96(2): 134-144.
17. Capitain O, Boisdron-Celle M, Poirier AL et al. The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer. Pharmacogenomics J 2008; 8(4): 256-267.
18. Cohen V, Panet-Raymond V, Sabbaghian N et al. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: A novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2003; 9(5): 1611-1615.
19. Etienne MC, Formento JL, Chazal M et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 2004; 14(12): 785-792.
20. Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005; 23(7): 1365-1369.
21. Lurje G, Zhang W, Yang D et al. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics 2008; 18(2): 161-168.
22. Marcuello E, Altes A, Menoyo A et al. Methylenetetrahydrofolate reductase gene polymorphisms: Genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol 2006; 57(6): 835-840.
23. Ruzzo A, Graziano F, Loupakis F et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007; 25(10): 1247-1254.
24. Ruzzo A, Graziano F, Loupakis F et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J 2008; 8(4): 278-288.
25. Suh KW, Kim JH, Kim DY et al. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene? Ann Surg Oncol 2006; 13(11): 1379-1385.
26. Terrazzino S, Agostini M, Pucciarelli S et al. A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. Pharmacogenet Genomics 2006; 16(11): 817-824.
27. Wisotzkey JD, Toman J, Bell T et al. MTHFR (C677T) polymorphisms and stage III colon cancer: Response to therapy. Mol Diagn 1999; 4(2): 95-99.
28. Zhang W, Press OA, Haiman CA et al. Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer. J Clin Oncol 2007; 25(24): 3726-3731.
29. Schwab M, Zanger UM, Marx C et al. German 5-FU Toxicity Study Group. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26(13): 2131-2138.
30. The Meta-Analysis Group In Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16(11): 3537-3541.
31. Shi M, Caprau D, Romitti P et al. Genotype frequencies and linkage disequilibrium in the CEPH human diversity panel for variants in folate pathway genes MTHFR, MTHFD, MTRR, RFC1, and GCP2. Birth Defects Res A Clin Mol Teratol 2003; 67(8): 545-549.
32. Jensen SA, Vainer B, Sorensen JB. The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil. Int J Cancer 2006; 120(3): 694-701.
33. Huang Y, Han S, Li Y et al. Different roles of MTHFR C677T and A1298C polymorphisms in colorectal adenoma and colorectal cancer: A meta-analysis. J Hum Genet 2007; 52(1): 73-85.
34. Friso S, Choi SW, Girelli D et al. A common mutation in the 5,10- methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci U S A 2002; 99(8): 5606-5611.
35. Jacques PF, Bostom AG, Williams RR et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93(1): 7-9.
36. Schwartz SM, Siscovick DS, Malinow MR et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997; 96(2): 412-417.
37. Yamada K, Chen Z, Rozen R, Matthews RG. Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proc Natl Acad Sci U S A 2001; 98(26): 14853-14858.